Literature DB >> 10969779

Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer.

M Esteller1, A Sparks, M Toyota, M Sanchez-Cespedes, G Capella, M A Peinado, S Gonzalez, G Tarafa, D Sidransky, S J Meltzer, S B Baylin, J G Herman.   

Abstract

Germ-line mutations in the tumor suppressor gene APC are associated with hereditary familial adenomatous polyposis (FAP), and somatic mutations are common in sporadic colorectal tumors. We now report that methylation in the promoter region of this gene constitutes an alternative mechanism for gene inactivation in colon and other tumors of the gastrointestinal tract. The APC promoter is hypermethylated in 18% of primary sporadic colorectal carcinomas (n = 108) and adenoma (n = 48), and neoplasia with APC methylation fails to express the APC transcript. Methylation affects only wild-type APC in 95% of cases and is not observed in tumors from FAP patients who have germ-line APC mutations. As with APC mutation, aberrant APC methylation occurs early in colorectal carcinogenesis. When other tumor types are analyzed (n = 208), methylation of the APC promoter is not restricted to the colon but is present in tumors originating elsewhere in the gastrointestinal tract but rarely in other tumors. Our data suggest that hypermethylation of APC provides an important mechanism for impairing APC function and further underscores the importance of the APC pathway in gastrointestinal tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969779

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  147 in total

Review 1.  Epigenetics of kidney cancer and bladder cancer.

Authors:  Amanda M Hoffman; Paul Cairns
Journal:  Epigenomics       Date:  2011-02       Impact factor: 4.778

Review 2.  New trends in molecular and cellular biomarker discovery for colorectal cancer.

Authors:  Parisa Aghagolzadeh; Ramin Radpour
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

3.  Promoter DNA hypermethylation in gastric biopsies from subjects at high and low risk for gastric cancer.

Authors:  Barbara G Schneider; Dun-Fa Peng; M Constanza Camargo; M Blanca Piazuelo; Liviu A Sicinschi; Robertino Mera; Judith Romero-Gallo; Alberto G Delgado; Luis E Bravo; Keith T Wilson; Richard M Peek; Pelayo Correa; Wael El-Rifai
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

Review 4.  Colorectal cancer: a model for epigenetic tumorigenesis.

Authors:  J J L Wong; N J Hawkins; R L Ward
Journal:  Gut       Date:  2006-07-13       Impact factor: 23.059

Review 5.  The canonical Wnt signalling pathway and its APC partner in colon cancer development.

Authors:  Jean Schneikert; Jürgen Behrens
Journal:  Gut       Date:  2006-07-13       Impact factor: 23.059

Review 6.  Molecular screening of cancer: the future is here.

Authors:  Sudhir Srivastava
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

7.  Wnt pathway may not be implicated in all routes to colorectal cancer.

Authors:  J R Jass
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

8.  Analysis of APC and IGFBP7 promoter gene methylation in Swedish and Vietnamese colorectal cancer patients.

Authors:  Jan Dimberg; Thai Trinh Hong; Marita Skarstedt; Sture Löfgren; Niklas Zar; Andreas Matussek
Journal:  Oncol Lett       Date:  2012-10-12       Impact factor: 2.967

9.  Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.

Authors:  Yutaka Suehiro; Chi Wai Wong; Lucian R Chirieac; Yutaka Kondo; Lanlan Shen; C Renee Webb; Yee Wai Chan; Annie S Y Chan; Tsun Leung Chan; Tsung-Teh Wu; Asif Rashid; Yuichiro Hamanaka; Yuji Hinoda; Rhonda L Shannon; Xuemei Wang; Jeffrey Morris; Jean-Pierre J Issa; Siu Tsan Yuen; Suet Yi Leung; Stanley R Hamilton
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

10.  Diet and epigenetics in colon cancer.

Authors:  Minna Nystrom; Marja Mutanen
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.